Key Takeaways
- Shares of Eli Lilly dropped approximately 3% Monday following an analyst’s discovery of a liver failure incident in FDA adverse event data connected to Foundayo, its oral GLP-1 medication
- The incident concerned a 56-year-old man; Lilly quickly refuted the connection, stating the case was unrelated to Foundayo
- Several Wall Street experts characterized the market reaction as excessive and indicated they would purchase shares at reduced prices
- Foundayo debuted last month and has quickly gained traction with 20,000 patients, 80% of whom are first-time GLP-1 users
- The pharmaceutical giant delivered impressive results with Mounjaro revenue surging 125% to $8.6B and Zepbound climbing 80% to $4.1B in the most recent quarter
Shares of Eli Lilly experienced a roughly 3% decline Monday morning following Evercore ISI analyst Umer Raffat’s identification of a hepatic failure incident within the FDA Adverse Event Reporting System (FAERS) associated with Foundayo, the company’s recently introduced oral GLP-1 medication.
The incident concerned a 56-year-old man and potentially took place on or prior to April 15. The documentation was filed with the FDA on April 30.
LLY shares were hovering around $934 during early Monday trading before experiencing a partial rebound. Competitor Novo Nordisk (NVO) climbed approximately 2% following the development.
Raffat emphasized that this single case shouldn’t be evaluated independently. He observed that hepatic failure incidents have been documented across various GLP-1 medications — Ozempic shows 33 recorded cases, Wegovy has 15, Mounjaro displays 30, and Zepbound reports 2.
He stated the “responsibility falls on LLY” to guarantee thorough and swift examination of liver-related cases to prevent misunderstanding, particularly considering previous worries surrounding hepatic toxicity with alternative oral GLP-1 compounds, including Pfizer’s candidate.
Lilly responded swiftly to the issue. The pharmaceutical company rejected the report following its determination that the case bore no connection to Foundayo.
Wolfe analyst Alexandria Hammond supported Lilly’s stance. She characterized the pre-market decline as “exaggerated” and expressed her intention to acquire shares during the weakness.
Bernstein’s Christian Moore shared this sentiment. He suggested it was improbable that a hepatic toxicity indication was overlooked considering the extensive clinical trial information produced for Foundayo, and similarly stated his plan to purchase during the decline.
Foundayo’s hepatic profile has undergone examination through numerous studies, including the 2,800-participant ACHIEVE-4 trial, which explored hepatic safety following the FDA’s inquiry and discovered no safety concerns.
Foundayo Demonstrates Strong Initial Performance
Foundayo made its market debut last month and has quickly attracted 20,000 patients. A significant observation: 80% of these individuals are completely new to GLP-1 medications, indicating the pill format is broadening the market rather than stealing from injectable product sales.
Foundayo possesses a convenience advantage over Novo Nordisk’s oral Wegovy — it doesn’t demand an empty stomach, simplifying integration into patients’ daily schedules.
Lilly is simultaneously making headway in physician outreach and establishing presence in mainstream pharmacy distribution networks.
Lilly’s Fundamental Performance Stays Robust
The stock decline occurred despite Lilly delivering impressive quarterly results the previous week. Mounjaro revenue skyrocketed 125% to $8.6 billion while Zepbound increased 80% to $4.1 billion.
Lilly controls approximately 60% of the U.S. market within the GLP-1 medication category, supported partly by head-to-head clinical trial evidence demonstrating better weight reduction compared to rival therapies.
The pharmaceutical company is pushing forward with additional weight management candidates throughout its development pipeline.
